Posted by Michael Wonder on 26 Mar 2021
FDA approves first in the world device to treat patients with congenital heart disease
26 March 2021 - New implant device provides less invasive option to treat pulmonary valve regurgitation for patients with a native or surgically-repaired right ventricular outflow tract.
Today, the U.S. FDA approved the first in the world non-surgical heart valve to treat paediatric and adult patients with a native or surgically-repaired right ventricular outflow tract, the part of the heart that carries blood out of the right ventricle to the lungs.
The device is designed for patients who have severe pulmonary valve regurgitation (blood leaking backward into the right lower chamber of the heart), a condition that often results from congenital heart disease.
